Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%

Interferon beta‐1a vs placebo

Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Very low

Interferon beta‐1a vs placebo

Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome

It is very uncertain whether interferon beta‐1a changes improvement in disability grade Defined as achievement of a… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.08 [0.42, 2.77]
1 study · 19 participants
Very low

Interferon beta‐1a vs placebo

Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Very low

Interferon beta‐1a vs placebo

Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interferon beta‐1a vs placebo

Death · patients with Guillain‐Barré syndrome

Interferon beta‐1a showed no clear difference in death compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.5 [0.07, 32.29]
1 study · 19 participants
Low

Interferon beta‐1a vs placebo

Death or disability after 12 months · patients with Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interferon beta‐1a vs placebo

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 0.92 [0.23, 3.72]
1 study · 19 participants
Very low